XML 42 R17.htm IDEA: XBRL DOCUMENT
v3.23.1

Equity | 3 Months Ended
--- | ---
Mar. 31, 2023
Equity [Abstract] |
Equity | Share Repurchases In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. There were no share repurchases of our common stock during the three months ended March 31, 2023 and 2022. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of March 31, 2023. Accumulated Other Comprehensive Income (Loss) The following tables summarize the changes in AOCI, net of tax by component:
|  | March 31, 2023
(In millions) |  | Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax |  | Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax |  |  |  | Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax |  | Currency Translation Adjustments |  | Total
Balance, December 31, 2022 |  | $ | (15.7) |  |  | $ | 15.1 |  |  |  |  | $ | (1.1) |  |  | $ | (163.2) |  |  | $ | (164.9) |
Other comprehensive income (loss) before reclassifications |  | 5.3 |  |  | (20.3) |  |  |  |  | 0.5 |  |  | 22.1 |  |  | 7.6 |
Amounts reclassified from AOCI |  | 0.4 |  |  | (15.1) |  |  |  |  | — |  |  | — |  |  | (14.7) |
Net current period other comprehensive income (loss) |  | 5.7 |  |  | (35.4) |  |  |  |  | 0.5 |  |  | 22.1 |  |  | (7.1) |
Balance, March 31, 2023 |  | $ | (10.0) |  |  | $ | (20.3) |  |  |  |  | $ | (0.6) |  |  | $ | (141.1) |  |  | $ | (172.0) |
|  | March 31, 2022
(In millions) |  | Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax |  | Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax |  | Gains (Losses) on Net Investment Hedges, Net of Tax(1) |  | Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax |  | Currency Translation Adjustments |  | Total
Balance, December 31, 2021 |  | $ | (2.2) |  |  | $ | 53.8 |  |  | $ | 25.5 |  |  | $ | (44.8) |  |  | $ | (139.0) |  |  | $ | (106.7) |
Other comprehensive income (loss) before reclassifications |  | (10.2) |  |  | 34.4 |  |  | 5.1 |  |  | 0.9 |  |  | (21.8) |  |  | 8.4 |
Amounts reclassified from AOCI |  | 0.5 |  |  | (18.5) |  |  | 1.1 |  |  | — |  |  | — |  |  | (16.9) |
Net current period other comprehensive income (loss) |  | (9.7) |  |  | 15.9 |  |  | 6.2 |  |  | 0.9 |  |  | (21.8) |  |  | (8.5) |
Balance, March 31, 2022 |  | $ | (11.9) |  |  | $ | 69.7 |  |  | $ | 31.7 |  |  | $ | (43.9) |  |  | $ | (160.8) |  |  | $ | (115.2) |
(1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements. The following table summarizes the amounts reclassified from AOCI:
(In millions) |  | Amounts Reclassified from AOCI |  | Income Statement Location
| For the Three Months Ended March 31, |  |  |
| 2023 |  | 2022 |  |  |  |  |
Gains (losses) on securities available for sale |  | $ | (0.5) |  |  | $ | (0.6) |  |  |  |  |  |  | Other (income) expense
|  | 0.1 |  |  | 0.1 |  |  |  |  |  |  | Income tax (benefit) expense
Gains (losses) on cash flow hedges |  | 17.6 |  |  | 20.9 |  |  |  |  |  |  | Revenue
|  | (0.5) |  |  | (0.3) |  |  |  |  |  |  | Operating expense
|  | (0.1) |  |  | (0.1) |  |  |  |  |  |  | Other (income) expense
|  | (1.9) |  |  | (2.0) |  |  |  |  |  |  | Income tax (benefit) expense
Gains (losses) on net investment hedges(1) |  | — |  |  | (1.1) |  |  |  |  |  |  | Other (income) expense
Total reclassifications, net of tax |  | $ | 14.7 |  |  | $ | 16.9 |  |  |  |  |  |  |
(1) Beginning in the second quarter of 2022 we no longer held net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read Note 2, Dispositions, to these condensed consolidated financial statements.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI https://asc.fasb.org/topic&trid=2208762 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (h) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 16 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (i) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 50 -Paragraph 6 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration